Serina concludes sentinel dosing in Phase Ib trial’s Cohort 1

Serina Therapeutics has completed sentinel dosing in Cohort 1 of its ongoing Phase Ib registrational trial assessing SER-252 in advanced Parkinson’s. The SER-252-1b study includes single-ascending-dose and multiple-ascending-dose components. The trial evaluates subcutaneous SER-252 versus placebo, using exploratory motor assessments. Credit: afotostock / Shutterstock.com. Serina Therapeutics has completed sentinel dosing in Cohort 1 of its ongoing Phase Ib registrational trial assessing SER-252 in adults with advanced Parkinson’s disease. The placebo-controlled, randomised, double-blind trial is being conducted at sites in Australia and the US, with plans to expand into South Korea and Taiwan during later study stages. LOA and PTSR Model…

Source: Clinical Trials Arena